Sunmary Bolus infusional 5-fluorouracil (5-FU) and folinic acid (FA) is reported to be highly active [partial response (PR) al., 1958), forming an irreversible ternary complex with TS and the co-factor 5,10-CH,-tetrahydrofolate (5,10-CH,-FH4). Reduced intracellular concentrations of 5,10-CH,-FH4 may therefore limit the formation of the ternary complex and hence limit the cytotoxicity of 5-FU. This hypothesis provides the rationale for the use of 5-FU in combination with folinic acid (5-CHO-FH4), which is readily converted to 5,10-CH2-FH4, increasing the formation of ternary complex. A number of clinical studies have shown that the combination of 5-FU with folinic acid enhances the activity of 5-FU in patients with metastatic colorectal cancer (Grem et al., 1987).
The fluorinated pynrmidine 5-fluorouracil (5-FU) is the most extensively used drug in metastatic colorectal cancer, although a meta-analysis (Advanced Colorectal Cancer Meta-Analysis Project, 1992) has shown that the response rate achieved using conventional bolus administration schedules is only 11%. Because of this low response rate, interest has focused on the modulation of 5-FU activity. A major locus of action of 5-FU is the enzyme thymidylate synthase (TS), the enzyme responsible for the formation of dTMP from dUMP. The 5-FU metabolite FdUMP is a potent inhibitor of TS (Cohen et al., 1958) , forming an irreversible ternary complex with TS and the co-factor 5,10-CH,-tetrahydrofolate (5,10-CH,-FH4). Reduced intracellular concentrations of 5,10-CH,-FH4 may therefore limit the formation of the ternary complex and hence limit the cytotoxicity of 5-FU. This hypothesis provides the rationale for the use of 5-FU in combination with folinic acid (5-CHO-FH4), which is readily converted to 5,10-CH2-FH4, increasing the formation of ternary complex. A number of clinical studies have shown that the combination of 5-FU with folinic acid enhances the activity of 5-FU in patients with metastatic colorectal cancer (Grem et al., 1987) .
Although the addition of folinic acid to 5-FU has been shown to improve response rates, this may occur at the expense of increased toxicity. In the initial reports of a widely used 5-FU/folinic acid combination administered to outpatients at weekly intervals [2 h infusion of folinic acid (500 mgm-2) with a bolus dose of 5-FU (600 mg m-2) administered 1 h into the folinic acid infusion] a high incidence (40%) of dose-limiting diarrhoea was observed (Petrelli et al., 1987) .
An alternative approach to the combination of 5-FU and folinic acid has been developed (De Gramont et al., 1988) . In this regimen a 2 h infusion of folinic acid (200 mg m-) is followed by both a bolus (300-500 mg m-2) and 22 h infusion (300-500 mg m-2) of 5-FU. This schedule is repeated on day 2 and repeated at 2 weekly intervals. Preliminary results demonstrated good activity (response rate = 54% CI 38-70%) and the regimen was well tolerated. In the initial 37 patients reported no WHO grade 3 toxicities were noted. A second study confirmed that the regimen is well tolerated, although response rates were lower: overall response=24% (95% CI 11-37%) (Johnson et al., 1991) ; overall response = 30% (n = 82) (Seymour et al.. 1994 Table I . Thirty patients (31% of patients) also received an infusion of 250mgm-' N-(phosphonacetyl)-L-aspartic acid (PALA) 24h prior to commencing bolus/infusional 5-FU/folinic acid. PALA is an inhibitor of the enzyme L-aspartic acid transcarbamoylase (ATCase), which is important in de novo pyrimidine synthesis and has been shown to modulate 5-FU activity (Martin et al.. 1983 ). PALA was administered in an out-patient clinic on the day prior to a 48 h admission for 5-EU folinic acid. Treatment was repeated at 2 weekly intervals provided that non-haematological toxicities (mucositis and diarrhoea) had resolved and that WBC was > 3.0 x I091' and platelets > 100 x I091-'. 5-FU was administered at three dose levels (E) Macmillan Press Ltd.. 1994 Br. J. Cancer (1994) . 70, [749] [750] [751] [752] Using a Cox proportional hazard model, the effect of symptoms (PS 1) vs no symptoms (PS 0) was not significant (relative hazard = 1. 17. 95% CI 0.61-2.24, y=0.24, I d.f., P = 0.62) in a survival analysis adjusting simultaneously for age. 5-FU dosage, primary site, PALA and liver function (ALP, AST, bilirubin) (Figure 2 ).
Toxicity associated with chemotherapy The regimen was generally well tolerated even at the higher 5-FU dosage (500 mg m-). One patient developed grade 3 diarrhoea in association with grade 4 leucopenia and died. This was considered to be a toxic death. Dosage was reduced as result of diarrhoea in seven patients (5;500-400 mg m2, 2; 400-300 mg m2) and mucositis in one patient (500-400 mg m2. In total, leucopenia was seen in three patients (two grade 4, one grade 2) and 5-FU dosage was reduced (500-400mgm-2) in one patient. Hand-foot syndrome led to dosage reduction in 1 patient (400-300 mg m2). Superficial thrombophlebitis was also noted in a number of patients and rhinitis with blood-stained mucus was described.
There did appear to be an increase in toxicity with the increased 5-FU dosage (Table III) (Figure 1) . However, the response rate and survival at the higher 5-FU dosage remains disappointing: (5 41 evaluable = 12%, 95% CI = 2-22%, median survival = 9 months).
The most common grade 3 toxicity was diarrhoea, and yet this occurred in only 6/43 (14%) patients treated at a 5-FU dosage of 500 mg m-2. In one patient severe toxicity including grade 4 neutropenia was encountered, and this patient probably died as a result of drug-induced toxicity. Sporadic severe toxicity has been previously reported in patients receiving 5-FU, and this phenomenon has been associated with evidence of reduced activity of the enzyme dihydropyrimidine dehydrogenase (DPD) (Lilenbaum et al.. 1991) . The low incidence of toxicity seen in our analysis and the improved survival with higher 5-FU dosage suggests that higher 5-FU dosage or 5-FU dose intensity may lead to improved anti-tumour activity. The dose intensity of the 5-FU/fohnic acid regimen used in the study reported here is 5-FU 1,000 mg m week ' and folinic acid 200 mg m week-'. In comparison, a regimen has been reported in which the 5-FU dose intensity (in combination with folinic acid) has been escalated to 2,600 mg m-' week-' and folinic acid dose intensity to 500 mg m2 week-' (Ardalan et al.. 1992) . In this study high response rates, albeit in small numbers of patients, have been reported.
We feel that the response rate and survival duration of the order seen in our analysis do not justify the cost of administration in terms of both drug costs and, in our experience in Glasgow. in-patient care. Patients were admitted fbr two nights every 2 weeks and this is likely to have a negative impact upon quality of life. In one patient this was stated as the cause of significant psychological morbidity and premature cessation of therapy. However, we are sensitive to the fact that this paper describes a retrospective analysis and are aware of the importance of performing carefully monitored prospective analyses of drug regimens. For this reason we are now accruing patients into a formal prospective analysis of this regimen at the higher 5-FU dosage (5 00 mg m -). In order to limit the number of patients treated using a potentially suboptimal regimen we have initiated a prospective phase II study using a sequential triangular procedure (Whitehead, 1983) for response analysis. On completion of this study we propose to explore the potential for dose,dose intensity escalation which we feel exists. In the meantime we caution against the use of the 5-FU/folinic acid regimen described in this paper as 'uncontrolled standard therapy'.
